UNSPSC 85254902: Diagnosis of benign neoplasm on the skin of eyelid, including canthus

This classification denotes the group of activities that yields a diagnosis of Benign neoplasm on the Skin of eyelid, including canthus. Benign neoplasm on the Skin of eyelid, including canthus is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as a four digit category under code D23.1

UNSPSC 85254902 Diagnosis of benign neoplasm on the skin of eyelid, including canthus is a Commodity code that shows no meaningful recent state and local procurement activity aligned with its clinical diagnostic scope. The three most recent opportunities posted under this code — a diagnostic imaging PACS system implementation by San Mateo Medical Center (RFP, due October 21, 2026), special education contracted services by Birdville Independent School District in Texas (RFP, due October 21, 2026), and a temporary health professional staffing pool by Santa Clara County Health System (RFQ, due October 7, 2026) — are each unrelated to eyelid neoplasm diagnosis. The PACS opportunity involves enterprise radiology and cardiology imaging infrastructure; the school district solicitation covers audiologists, speech therapists, and behavioral specialists; and the county health system seeks temporary clinical staff across audiology, cardiology, diagnostic imaging, and surgical services. None of these procurements target the specific diagnostic work product named in the code.

The mismatch between the code's clinical descriptor and the actual work being solicited suggests either a taxonomic labeling error in state and local procurement systems or that this code does not represent active state and local purchasing. No geographic concentration, issuing-body pattern, or pipeline of related opportunities emerges from the available record. Business development professionals should verify whether this code is actively used in their target jurisdictions' procurement workflows before investing pursuit effort; the evidence does not support current market activity.